Fiocruz is an arm of the Brazilian Ministry of Health and alfataliglicerase is the company’s enzyme replacement therapy for the rare lysosomal storage disorder.
Protalix president and CEO David Aviezer said, "We are encouraged by the recognition of our drug and our technology by both Fiocruz and Brazil’s Ministry of Health, and believe that this agreement will further establish a reliable supply of treatment for patients living with Gaucher disease."
As per the terms of the agreement, Fiocruz will purchase $40m of UPLYSO during the first two years of the agreement.
In the following years, Fiocruz is required to purchase UPLYSO at a minimum price value of $40m every year.
Besides, Protalix may not complete the final stage of the technology transfer until Fiocruz purchases a minimum of $280m worth of UPLYSO.
Brazil Health minister Alexandre Padilha said, "Through this collaboration, we are able to strengthen our technological and industrial capabilities in the area of biologics manufacturing and improve the health of Brazilian citizens who are impacted by this rare disorder."
In order to complete the technology transfer, the deal may be extended for an additional term of five-years.
UPLYSO is distributed as ELELYSO in the US and Israel.